They need a substantial increase in the revenue for products this quarter and I mean more than double the PCP for revenue and or secure a major services contract. However, they aren't in the scope of doing that as they seem full on with their own sexual health product, the Hologic work and up ramping of Febridx and Viradx.
They simply need to cut the costs and trim the fat, whilst utilising the credit facilities available.
Add to My Watchlist
What is My Watchlist?
